Nervous Disorder TRIZ Cases

GPR30/GPER agonists reduce oxidative stress by inhibiting Nox-associated reactive oxygen species production.

Retinoic acid and signaling pathway manipulations reduce culture time from 150 days to 75 days while achieving high purity.

Catalytically inactive clostridial neurotoxin polypeptides treat pain and inflammatory disorders without toxic side effects from SNARE protein cleavage.

Raney nickel catalyzes hydrogen reduction of nitrile precursors in acetic anhydride media, resolving purity trade-offs while achieving yields above 85 percent.

Nucleophilic substitution creates a phthalimide intermediate, eliminating high-pressure hydrogenation requirements during agomelatine synthesis.

Passive transfer of human anti-tau antibodies avoids active immunization immune responses while targeting pathological tau.

Disulfide-constrained peptides inhibit serine proteases to protect therapeutic proteins from enzymatic degradation.

Novel 2-aminobenzenesulfonamide derivatives inhibit the sodium-potassium-chloride cotransporter to modulate intracellular chloride levels.

Specific amino acid modifications in AAV capsids increase CNS transduction efficiency while evading pre-existing antibody neutralization.

TfR-binding polypeptides transport therapeutic agents across the blood-brain barrier, resolving rapid clearance issues to sustain brain exposure.

Ginkgoloides inhibit alkyl-acyl-GPC binding to prevent albumin depletion and hypersensitivity syndromes while equilibrating hormonal metabolism.

Controlled esketamine plasma concentrations maintain therapeutic efficacy while minimizing mutagenicity risks in major depressive disorder treatment.

Administering SJNNV stimulates interferon-inducible gene expression, reducing mortality and disease symptoms when fish are exposed to RGNNV.

Dried reconstituted vesicles form multilamellar liposomes via fusion agents, avoiding harsh freeze-thaw cycles that degrade protein stability during storage.

Intranasal caffeine extract provides rapid systemic absorption to alleviate withdrawal symptoms while maintaining nil-by-mouth status.

Conjugating anti-Gal3 antibodies with transferrin enables blood-brain barrier penetration for treating neurological disorders.

A specific peptide carrier traverses the blood-brain barrier to deliver therapeutic agents directly to neurodegenerative disease sites.

Novel molecular markers identify dopaminergic neural precursor cells for precise isolation and therapeutic application.

Anti-MCAM antibodies bind MCAM on TH17 cells to block laminin alpha-4 interaction, preventing CNS infiltration in neuroinflammatory conditions.

An effervescent pharmaceutical formulation of pyridoxal-5-phosphate accelerates dissolution through carbon dioxide release and sodium salt formation.

Palmitoylethanolamine mediates opioid receptor activation to reduce irritation, confusion, and uncontrolled movement while maintaining analgesic efficacy.

Intravenous AAV particles transduce nervous system structures, resolving distribution inefficiency in Friedreich's Ataxia treatment.

Segmenting molecular structures yields a selective AT2 inhibitor that controls bone resorption without affecting AT1 receptors.

Plasminogen promotes GLP-1 expression to improve glucose tolerance while managing diabetes treatment complexity.

Adenovirus-associated viral vectors deliver lysosomal enzyme genes via the nasal route to restore cellular function in brain tissue.

AAV5 vector delivers variant parkin gene to neurons, restoring functional protein expression and increasing dopaminergic neuron counts.

Co-transplanting irradiated monocytes with stem cells creates a protective microenvironment that increases survival rates and therapeutic efficacy.

Pyridinylsulfonamide compounds inhibit MALT1 activity, addressing adverse side effects of current cancer therapies.

SR59230A derivatives enhance p53 acetylation and induce apoptosis to overcome limited therapeutic options for malignant tumors.

Purified cannabidiol treatment eliminates neurological damage from intractable seizures linked to chromosomal abnormalities.

Engineered humanized anti-IL-20 antibodies reduce immunogenicity while preserving binding affinity to treat osteoporosis and inflammatory diseases.

A method determines PER3 VNTR genotype to predict individual sleep parameters and treatment response.

Hexokinase 2 inhibitors suppress microglial glycolysis to resolve cerebral hemorrhage and edema risks during acute ischemic stroke treatment.

GCPQ nanoparticles cross the nasal mucosa to bypass enzymatic degradation and improve bioavailability.

Oxovanadium complexes with alpha-hydroxypyranone ligands deliver analgesia without gastrointestinal side effects or addiction risks.

Modified HSV-1 strain HL-1 improves tumor cell killing and antitumor immune response through specific gene knockout.

Single amino acid substitutions at position 11 of the light chain CDR1 enhance stability against pH and temperature stress while preserving biological potency.

Combining a beta-AR agonist with a peripherally acting blocker targets brain activity to improve cognitive function in ALS patients.

Acid-sensitive alginoketal particles release cations through endosomal hydrolysis, eliminating organic solvent requirements.

Antibody-conjugated magnetic nanoparticles enable direct extraction of viable neural stem cells from adult brains, bypassing fetal tissue reliance.